Inhibition of Monoamine Oxidase by Anithiactins from Streptomyces sp. |
Lee, Hyun Woo
(Department of Pharmacy, Sunchon National University)
Jung, Won Kyeong (Research Institute of Life Pharmaceutical Sciences, Sunchon National University) Kim, Hee Jung (Department of Pharmacy, Sunchon National University) Jeong, Yu Seok (Department of Pharmacy, Sunchon National University) Nam, Sang-Jip (Department of Chemistry and Nano Science, Ewha Women’s University) Kang, Heonjoong (Center for Marine Natural Products and Drug Discovery, School of Earth and Environmental Sciences, Seoul National University) Kim, Hoon (Department of Pharmacy, Sunchon National University) |
1 | Gentili F, Pizzinat N, Ordener C, Marchal-Victorion S, Maurel A, Hofmann R, et al. 2006. 3-[5-(4,5-Dihydro-1Himidazol-2-yl)-furan-2-yl]phenylamine (amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J. Med. Chem. 49: 5578-5586. DOI |
2 | Kim H, Sablin SO, Ramsay RR. 1997. Inhibition of monoamine oxidase A by β-carboline derivatives. Arch. Biochem. Biophys. 337: 137-142. DOI |
3 | Kim H, Yang I, Patil RS, Kang S, Lee J, Choi H, et al. 2014. Anithiactins AC, modified 2-phenylthiazoles from a mudflatderived Streptomyces sp. J. Nat. Prod. 77: 2716-2719. DOI |
4 | Lin Z, Antemano RR, Hughen RW, Tianero MD, Peraud O, Haygood MG, et al. 2010. Pulicatins A-E, neuroactive thiazoline metabolites from cone snail-associated bacteria. J. Nat. Prod. 73: 1922-1926. DOI |
5 | Lotufo-Neto F, Trivedi M, Thase ME. 1999. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 20: 226-247. DOI |
6 | Malcomson T, Yelekci K, Borrello MT, Ganesan A, Semina E, De Kimpe N, et al. 2015. cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases. FEBS J. DOI: 10.1111/febs.13260 [Epub ahead of print]. DOI |
7 | Finberg JP. 2014. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol. Ther. 143: 133-152. DOI |
8 | Fowler JS, Logan J, Azzaro AJ, Fielding RM, Zhu W, Poshusta AK, et al. 2010. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAOA by CX157. Neuropsychopharmacology 35: 623-631. DOI |
9 | Abdelhafez OM, Amin KM, Ali HI, Abdalla MM, Batran RZ. 2012. Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors. J. Med. Chem. 55: 10424-10436. DOI |
10 | Bautista-Aguilera OM, Samadi A, Chioua M, Nikolic K, Filipic S, Agbaba D, et al. 2014. N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl) prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. J. Med. Chem. 57: 10455-10463. DOI |
11 | Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ. 1990. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br. J. Clin. Pharmacol. 30: 805-816. DOI |
12 | Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L, et al. 2006. Evidence for a control of plasma serotonin levels by 5-hydroxytryptamine (2B) receptors in mice. J. Pharmacol. Exp. Ther. 317: 724-731. DOI |
13 | Youdim MB, Edmondson D, Tipton KF. 2006. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7: 295-309. DOI |
14 | Doly S, Valjent E, Setola V, Callebert J, Hervé D, Launay JM, Maroteaux L. 2008. Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro. J. Neurosci. 28: 2933-2940. DOI |
15 | Fenical W, Jensen PR. 2006. Developing a new resource for drug discovery: marine actinomycete bacteria. Nat. Chem. Biol. 2: 666-673. DOI |
16 | Ferino G, Vilar S, Matos MJ, Uriarte E, Cadoni E. 2012. Monoamine oxidase inhibitors: ten years of docking studies. Curr. Top. Med. Chem. 12: 2145-2162. DOI |
17 | Mattsson C, Svensson P, Sonesson C. 2014. A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors. Eur. J. Med. Chem. 73: 177-186. DOI |
18 | Moon K, Chung B, Shin Y, Rheingold AL, Moore CE, Park SJ, et al. 2015. Pentacyclic antibiotics from a tidal mud flatderived actinomycete. J. Nat. Prod. 78: 524-529. DOI |
19 | Mostert S, Petzer A, Petzer JP. 2015. Indanones as high-potency reversible inhibitors of monoamine oxidase. ChemMedChem DOI: 10.1002/cmdc.201500059 [Epub ahead of print]. DOI |
20 | Pan HQ, Yu SY, Song CF, Wang N, Hua HM, Hu JC, Wang SJ. 2015. Identification and characterization of the antifungal substances of a novel Streptomyces cavourensis NA4. J. Microbiol. Biotechnol. 25: 353-357. DOI |
21 | Parsons CG, Danysz W, Dekundy A, Pulte I. 2013. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotox. Res. 24: 358-369. DOI |
22 | Yang W, Dostal L, Rosazza JP. 1993. Aeruginol [2-(2’-hydroxyphenyl)-4-hydroxymethylthiazole], a new secondary metabolite from Pseudomonas aeruginosa. J. Nat. Prod. 56: 1993-1994. DOI |
23 | Ramsay RR. 2012. Monoamine oxidases: the biochemistry of the proteins as targets in medicinal chemistry and drug discovery. Curr. Top. Med. Chem. 12: 2189-2209. DOI |
24 | Ramsay RR. 2013. Inhibitor design for monoamine oxidases. Curr. Pharm. Des. 19: 2529-2539. DOI |
25 | Stevens H, Brinkhoff T, Rink B, Vollmers J, Simon M. 2007. Diversity and abundance of gram positive bacteria in a tidal flat ecosystem. Environ. Microbiol. 9: 1810-1822. DOI |
![]() |